SLNO Soleno Therapeutics Corp: Price-to-Projected Revenue Ratio

Soleno Therapeutics - graphic logo of issuer SLNO

Soleno Therapeutics (SLNO) is developing DCCR, a unique drug for the treatment of Prader-Willi syndrome, holding exclusive orphan drug status. A team of elite endocrinologists is driving innovation supported by robust laboratory funding. The humanitarian nature of these projects minimizes geopolitical risks and sanctions. The future P/S multiple reflects the business valuation dynamics, where the value 2.40 serves as the baseline indicator of current market value.

Soleno Therapeutics, Inc. - SLNO Market Cap to Expected Sales Ratio (period 08/08/2025 - 05/30/2026)

Summary analytical data breakdowns for soleno.life (SLNO)

- market price and analyst price targets:
Comprehensive company analysis:SLNO (soleno.life)
Original product of Soleno Therapeutics

The forward P/S ratio relates the current market value of the business to expected sales volume, allowing investors to assess the premium paid for future growth without the delays associated with quarterly reports. By analyzing the projected price-to-sales valuation, one can filter out speculative noise, which is critical for Soleno Therapeutics (SLNO), where the automation of drug synthesis accelerates development, yet final capitalization depends on lengthy clinical trials.

Competitor analysis

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio